Treatment After Crizotinib Resistance in ALK + Non-Small-Cell Lung Cancer

@inproceedings{Kazaz2017TreatmentAC,
  title={Treatment After Crizotinib Resistance in ALK + Non-Small-Cell Lung Cancer},
  author={Seher Nazlı Kazaz and Ilhan Oztop},
  year={2017}
}
Systemic chemotherapy, genotype-based targeted therapies and immunotherapy are widely used in the treatment of advanced nonsmall-cell lung cancer (NSCLC). Among the targeted therapies, the agents targeting the epidermal growth factor receptor (EGFR), the echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK) rearrangement and… CONTINUE READING